This c-Myc-driven tumor derived from both the GEMM and human tumors (recently named SCLC-N) tends to express high levels of NEUROD1 (neuronal differentiation 1; a master transcriptional regulator of neural development) and low levels of neuroendocrine markers, in contrast with L-MYC-driven tumors (recently named the SCLC-A subtype), which express high levels of both ASCL1 (achaete-scute homolog 1; another regulator of neural differentiation) and neuroendocrine markers, including SYP and CGRP6,9,20,97–99. Here, MYCL is linked to neoplasm.